High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing. Methods: COVID-19 positive patients admitted to the h...

Descripción completa

Detalles Bibliográficos
Autores principales: Karolyi, Mario, Omid, Sara, Pawelka, Erich, Jilma, Bernd, Stimpfl, Thomas, Schoergenhofer, Christian, Laferl, Hermann, Seitz, Tamara, Traugott, Marianna, Wenisch, Christoph, Zoufaly, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282360/
https://www.ncbi.nlm.nih.gov/pubmed/34276386
http://dx.doi.org/10.3389/fphar.2021.704767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282360/
https://www.ncbi.nlm.nih.gov/pubmed/34276386
http://dx.doi.org/10.3389/fphar.2021.704767

Ejemplares similares